Literature DB >> 15164874

p21-activated kinase 1: an emerging therapeutic target.

Ratna K Vadlamudi1, Rakesh Kumar.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15164874     DOI: 10.1007/1-4020-7847-1_5

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


× No keyword cloud information.
  5 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.

Authors:  Julien Viaud; Jeffrey R Peterson
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

3.  Individual and combined soy isoflavones exert differential effects on metastatic cancer progression.

Authors:  Michelle M Martínez-Montemayor; Elisa Otero-Franqui; Joel Martinez; Alina De La Mota-Peynado; Luis A Cubano; Suranganie Dharmawardhane
Journal:  Clin Exp Metastasis       Date:  2010-06-02       Impact factor: 5.150

4.  Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling.

Authors:  Jun Du; Chongqi Sun; Zhenzhen Hu; Yu Yang; Yichao Zhu; Datong Zheng; Luo Gu; Xiang Lu
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

5.  In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.

Authors:  Abdel Aouacheria; Vincent Navratil; Ricardo López-Pérez; Norma C Gutiérrez; Alexander Churkin; Danny Barash; Dominique Mouchiroud; Christian Gautier
Journal:  BMC Genomics       Date:  2007-01-03       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.